Fresenius Medical Care AG (NYSE:FMS) Stake Lessened by Valley National Advisers Inc.

Valley National Advisers Inc. decreased its position in shares of Fresenius Medical Care AG (NYSE:FMS) by 31.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,936 shares of the company’s stock after selling 3,662 shares during the period. Valley National Advisers Inc.’s holdings in Fresenius Medical Care were worth $179,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Allworth Financial LP raised its stake in shares of Fresenius Medical Care by 53.1% in the 3rd quarter. Allworth Financial LP now owns 1,675 shares of the company’s stock worth $36,000 after buying an additional 581 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new position in Fresenius Medical Care during the third quarter worth about $38,000. GAMMA Investing LLC raised its position in Fresenius Medical Care by 50.4% in the third quarter. GAMMA Investing LLC now owns 4,998 shares of the company’s stock worth $106,000 after acquiring an additional 1,675 shares in the last quarter. ORG Wealth Partners LLC acquired a new stake in Fresenius Medical Care in the 3rd quarter valued at about $112,000. Finally, Venturi Wealth Management LLC boosted its position in shares of Fresenius Medical Care by 1,045.8% during the 3rd quarter. Venturi Wealth Management LLC now owns 5,259 shares of the company’s stock valued at $112,000 after purchasing an additional 4,800 shares in the last quarter. 8.37% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms recently commented on FMS. Truist Financial increased their target price on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the company a “hold” rating in a research note on Monday, January 6th. Bank of America upgraded Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research report on Monday, December 2nd. StockNews.com began coverage on Fresenius Medical Care in a report on Friday, January 3rd. They issued a “strong-buy” rating on the stock. Finally, Berenberg Bank started coverage on Fresenius Medical Care in a report on Wednesday, November 6th. They set a “buy” rating and a $25.60 target price for the company.

Fresenius Medical Care Stock Performance

Fresenius Medical Care stock opened at $24.89 on Monday. Fresenius Medical Care AG has a fifty-two week low of $17.93 and a fifty-two week high of $25.25. The firm’s 50 day simple moving average is $23.20 and its 200-day simple moving average is $21.23. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02. The company has a market cap of $14.60 billion, a P/E ratio of 20.57, a price-to-earnings-growth ratio of 0.82 and a beta of 0.92.

Fresenius Medical Care (NYSE:FMS) last posted its quarterly earnings data on Tuesday, November 5th. The company reported $0.45 earnings per share for the quarter, topping the consensus estimate of $0.42 by $0.03. The firm had revenue of $5.23 billion for the quarter, compared to analysts’ expectations of $5.36 billion. Fresenius Medical Care had a net margin of 3.43% and a return on equity of 6.04%. During the same period in the previous year, the company posted $0.31 EPS. As a group, equities research analysts predict that Fresenius Medical Care AG will post 1.53 EPS for the current year.

Fresenius Medical Care Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.